Why the RSV Vaccine Advice Moved From Your Choice to Your Age

In 2023, the Advisory Committee on Immunization Practices told adults 60 and older that they may receive a single RSV vaccine dose through "shared clinical decision-making," which placed the choice inside each conversation with a clinician. In June 2024, the committee replaced that open-ended language with a rule tied to age and risk: everyone 75 and older should receive a dose, and adults 60 to 74 should receive one if they carry conditions that raise their risk of severe disease. Nothing about the vaccines' measured efficacy forced the switch. What changed was the evidence on how the first recommendation performed once real clinics tried to use it.

What "shared clinical decision-making" actually meant

ACIP issues a small set of recommendation types, and shared clinical decision-making is the softest one on the list. It is not a routine recommendation for everyone, and it is not a targeted recommendation for a defined group. It signals that the evidence supports vaccination for some people but does not cleanly identify who, so the committee hands the judgment to the individual patient and clinician. The 2023 statement (MMWR 2023) applied exactly this label to all adults 60 and older after the FDA approved the first two protein subunit vaccines. The trials showed moderate to high efficacy against RSV-associated lower respiratory tract disease, which is why the committee did not withhold a recommendation. The uncertainty was about breadth, not about whether the vaccines worked.

The signal that the category was failing

The problem surfaced in how the recommendation behaved. A "may receive" instruction asks every eligible patient and every clinician to run a personalized risk conversation, and those conversations are slow, uneven, and easy to defer in a crowded visit. A vaccination program succeeds only if doses reach the arms that need them, and the recommendation is one of the main levers that decides whether they do. Coverage in the first season landed well below what a routine recommendation for a clearly defined group would produce, and uptake was uneven across the population. When a policy's effect depends on thousands of separate discussions, the people who would benefit most are often not the ones who end up protected. The 2024 update (MMWR 2024) states its aim plainly: to maximize coverage among the people most likely to benefit. That is a feasibility argument, not an efficacy argument.

Where the age line was drawn, and why 75

Risk of severe RSV is not flat across the span from 60 upward. Hospitalization and death climb steeply with age and with the accumulation of chronic conditions, and the burden in the mid-70s and beyond runs substantially higher than in the low 60s. Setting the universal line at 75 puts a clean, checkable rule where the net benefit is least ambiguous. A clinician no longer has to weigh competing factors; the patient's age answers the question. The cost of a bright line is that a few lower-risk 74-year-olds fall just outside it while some robust 76-year-olds fall just inside, yet a rule clinics can apply consistently reaches more of the right people than one that depends on judgment reached case by case. That is the point: it converts a recommendation that required deliberation into one a health system can measure, prompt on, and audit.

Why 60 to 74 stayed risk-based

For the younger band the committee kept a targeted rule rather than extending the universal one, and a safety signal is part of why. Early post-marketing surveillance (MMWR 2024) found Guillain-Barre syndrome reported after vaccination at rates above the expected background: roughly 4.4 reports per million doses for one product and 1.8 per million for the other, set against about 10.6 million adults vaccinated in the first season. These are passive reports, which cannot establish causation and are prone to bias, and the absolute risk is low. But when expected benefit is lower, as it is for a healthier person in their early 60s, even a small possible harm carries more weight in the balance. Reserving the recommendation for adults 60 to 74 with heart disease, lung disease, diabetes, obesity, weakened immunity, or frailty concentrates the vaccine where the benefit most clearly exceeds the uncertainty.

Implementation as evidence

The deeper lesson is methodological. ACIP's Evidence to Recommendations framework does not score only efficacy and safety. It also weighs acceptability, feasibility, resource use, and equity, and those domains carry real weight in the final vote. Shared clinical decision-making scored well on the science and poorly on the delivery: it was hard to put into practice, it produced low and unequal uptake, and it left clinicians without a clear way to prioritize. The 2024 revision treats that delivery record as data. How a recommendation performs in the field, not only how the product performs in a trial, becomes evidence that can move the recommendation itself.

That reframing reaches beyond RSV. Efficacy is measured before a product meets the public; implementability shows itself only afterward. A category that looks reasonable on paper can fail in practice by asking too much of a single encounter, and that failure is measurable in coverage and equity gaps. The same logic applies to any preventive service whose value depends on wide, even reach rather than on a one-time individual choice. Reading those numbers as evidence, and acting on them, is what separates a static guideline from one that learns from its own rollout.

This article is educational and is not medical advice; decisions about any vaccine belong in a conversation with your own clinician.